T hrough December 31, 2007, the Food and Drug Administration (FDA) approved 17 New Molecular Entities (NMEs). This number does not include the 2 Biologic License Application (BLA) Approvals. NMEs approved during 2007 are listed in Table 1 ; this information is made available by the FDA at: http://www.fda.gov/ cder/rdmt/InternetNME07.htm.
An average of 21 NMEs a year were approved in the 5 years prior to 2007. Much has been made in the media regarding FDA delays in the approval process contributing to the lower number of approvals; however, this does not appear to be the case. In 1996, the median total FDA-approval time for priority and standard NMEs was 9.6 and 15.1 months, respectively. In 2006, the median total approval time (including both NMEs and BLAs) was 6 months for priority drug approvals and 13.7 months for standard approvals. Review and approval times for drugs approved in 2007 have not been made available.
Another touted cause for the seeming drought in approvals is the lack of innovation of the pharmaceutical industry. Has the industry shifted emphasis to finding uses for agents already approved for other indications or making structural manipulations of drugs already FDA approved? Neither of these seems to be the case. In 2007, we see the first treatment for One additional factor to consider is the rising number of BLA approvals in recent years. The FDA has approved an increasing number of BLAs in recent years. The paucity of NME approvals in 2007 has been more than offset.
Overall, in the external envi-ronment, fingers are being pointed to either the FDA or the industry. However, there may be a new element of caution within the FDA and pharmaceutical industry. If this is the case, compromising the rate of innovation and number of NME approvals for patient safety is welcome.
Dear Editor, I just read the editorial titled "It's Time to Clean Up <797>" by Michael Sanborn (in the March 2007 issue of Hospital Pharmacy). If it is not too late, I would like to comment on this issue. I am an oncology pharmacy manager in a private practice that has 3 satellite clinics. Each of our sites admixes chemotherapy for our patients. Each site is unique in terms of shape and size of course. Each site does have a vertical biological safety cabinet in which chemotherapy is mixed for our patients.
I recently applied to the New Mexico Board of Pharmacy for clinic licensure in each site. The inspector was very concerned about USP <797> regulations and our adherence to them. I spent a tremendous amount of time and energy writing policies and procedures and attempted to incorporate as many of the <797> recommendations as possible in order to get licensed. The inspector mentioned items such as wiping down every bag with alcohol prior to taking it into the clean room, which I find not only a waste of time, but do not see what good it will do and that the most important thing is to use good aseptic technique.
I am very concerned as to the impact this chapter will have on our practice if it is someday enforced. I completely agree with Mr. Sanborn's assessment of the issue in that the most important aspect to providing a sterile product and protecting our patients from potential microbial contamination is aseptic technique.
Thank you for your attention.
-Jose Montoya, RPh Oncology Pharmacy Manager Albuquerque, NM
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